196 related articles for article (PubMed ID: 15700833)
1. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma.
Nishikawa R; Sugiyama T; Narita Y; Furnari F; Cavenee WK; Matsutani M
Brain Tumor Pathol; 2004; 21(2):53-6. PubMed ID: 15700833
[TBL] [Abstract][Full Text] [Related]
2. Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.
Mishima K; Johns TG; Luwor RB; Scott AM; Stockert E; Jungbluth AA; Ji XD; Suvarna P; Voland JR; Old LJ; Huang HJ; Cavenee WK
Cancer Res; 2001 Jul; 61(14):5349-54. PubMed ID: 11454673
[TBL] [Abstract][Full Text] [Related]
3. Molecular characterization of EGFR and EGFRvIII signaling networks in human glioblastoma tumor xenografts.
Johnson H; Del Rosario AM; Bryson BD; Schroeder MA; Sarkaria JN; White FM
Mol Cell Proteomics; 2012 Dec; 11(12):1724-40. PubMed ID: 22964225
[TBL] [Abstract][Full Text] [Related]
4. Regulation of HGF expression by ΔEGFR-mediated c-Met activation in glioblastoma cells.
Garnett J; Chumbalkar V; Vaillant B; Gururaj AE; Hill KS; Latha K; Yao J; Priebe W; Colman H; Elferink LA; Bogler O
Neoplasia; 2013 Jan; 15(1):73-84. PubMed ID: 23359207
[TBL] [Abstract][Full Text] [Related]
5. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor.
Jungbluth AA; Stockert E; Huang HJ; Collins VP; Coplan K; Iversen K; Kolb D; Johns TJ; Scott AM; Gullick WJ; Ritter G; Cohen L; Scanlan MJ; Cavenee WK; Old LJ
Proc Natl Acad Sci U S A; 2003 Jan; 100(2):639-44. PubMed ID: 12515857
[TBL] [Abstract][Full Text] [Related]
6. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma.
Inda MM; Bonavia R; Mukasa A; Narita Y; Sah DW; Vandenberg S; Brennan C; Johns TG; Bachoo R; Hadwiger P; Tan P; Depinho RA; Cavenee W; Furnari F
Genes Dev; 2010 Aug; 24(16):1731-45. PubMed ID: 20713517
[TBL] [Abstract][Full Text] [Related]
7. Analysis of phosphotyrosine signaling in glioblastoma identifies STAT5 as a novel downstream target of ΔEGFR.
Chumbalkar V; Latha K; Hwang Y; Maywald R; Hawley L; Sawaya R; Diao L; Baggerly K; Cavenee WK; Furnari FB; Bogler O
J Proteome Res; 2011 Mar; 10(3):1343-52. PubMed ID: 21214269
[TBL] [Abstract][Full Text] [Related]
8. The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling.
Huang HS; Nagane M; Klingbeil CK; Lin H; Nishikawa R; Ji XD; Huang CM; Gill GN; Wiley HS; Cavenee WK
J Biol Chem; 1997 Jan; 272(5):2927-35. PubMed ID: 9006938
[TBL] [Abstract][Full Text] [Related]
9. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
10. Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.
Gilder AS; Jones KA; Hu J; Wang L; Chen CC; Carter BS; Gonias SL
J Biol Chem; 2015 Jun; 290(24):14798-809. PubMed ID: 25837250
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.
Nagane M; Levitzki A; Gazit A; Cavenee WK; Huang HJ
Proc Natl Acad Sci U S A; 1998 May; 95(10):5724-9. PubMed ID: 9576951
[TBL] [Abstract][Full Text] [Related]
12. Sym004-induced EGFR elimination is associated with profound anti-tumor activity in EGFRvIII patient-derived glioblastoma models.
Keir ST; Chandramohan V; Hemphill CD; Grandal MM; Melander MC; Pedersen MW; Horak ID; Kragh M; Desjardins A; Friedman HS; Bigner DD
J Neurooncol; 2018 Jul; 138(3):489-498. PubMed ID: 29564747
[TBL] [Abstract][Full Text] [Related]
13. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA.
Halatsch ME; Schmidt U; Bötefür IC; Holland JF; Ohnuma T
J Neurosurg; 2000 Feb; 92(2):297-305. PubMed ID: 10659018
[TBL] [Abstract][Full Text] [Related]
14. Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence.
Mukasa A; Wykosky J; Ligon KL; Chin L; Cavenee WK; Furnari F
Proc Natl Acad Sci U S A; 2010 Feb; 107(6):2616-21. PubMed ID: 20133782
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation-induced conformational modification positively regulates receptor-receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/DeltaEGFR) expressed in cancer cells.
Fernandes H; Cohen S; Bishayee S
J Biol Chem; 2001 Feb; 276(7):5375-83. PubMed ID: 11087732
[TBL] [Abstract][Full Text] [Related]
16. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas.
Narita Y; Nagane M; Mishima K; Huang HJ; Furnari FB; Cavenee WK
Cancer Res; 2002 Nov; 62(22):6764-9. PubMed ID: 12438278
[TBL] [Abstract][Full Text] [Related]
17. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter.
Latha K; Li M; Chumbalkar V; Gururaj A; Hwang Y; Dakeng S; Sawaya R; Aldape K; Cavenee WK; Bogler O; Furnari FB
Int J Cancer; 2013 Feb; 132(3):509-20. PubMed ID: 22729867
[TBL] [Abstract][Full Text] [Related]
18. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
Taylor TE; Furnari FB; Cavenee WK
Curr Cancer Drug Targets; 2012 Mar; 12(3):197-209. PubMed ID: 22268382
[TBL] [Abstract][Full Text] [Related]
19. A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis.
Nagane M; Coufal F; Lin H; Bögler O; Cavenee WK; Huang HJ
Cancer Res; 1996 Nov; 56(21):5079-86. PubMed ID: 8895767
[TBL] [Abstract][Full Text] [Related]
20. Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Learn CA; Hartzell TL; Wikstrand CJ; Archer GE; Rich JN; Friedman AH; Friedman HS; Bigner DD; Sampson JH
Clin Cancer Res; 2004 May; 10(9):3216-24. PubMed ID: 15131063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
